First International Symposium on Cardiac Sympathetic Neuroimaging
In conjunction with the 19th International Symposium of the American Autonomic Society (AAS)
Organizers: D. S. Goldstein and S. Orimo
Marriott Kauai Resort Hotel
Lihue, Kauai, Hawaii
October 29, 2008

Buffet breakfast and sign-in
Welcome and background. D.S. Goldstein, NINDS, NIH, Bethesda, MD USA
D.S. Goldstein, NINDS, NIH, Bethesda, MD USA
Cardiac and extra-cardiac noradrenergic denervation in Parkinson disease (also Poster #S14)
P.H. Lee, Ajou University School of Medicine, Suwon, Korea
Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson’s disease (also Poster #S15)
G. Wenning, University of Innsbruck, Austria
Brain and cardiac neuroimaging to distinguish Parkinson’s disease from multiple system atrophy (also Poster #S16)
S. Orimo, Kanto Central Hospital, Tokyo, Japan
Cardiac noradrenergic denervation in Lewy body disease: Clinical-pathologic correlations (also Poster #S17)
Coffee/juice break
S. Kasama, Gunma University School of Medicine, Gunma, Japan
Effects of candesartan on cardiac sympathetic nerve activity in patients with chronic heart failure and preserved left ventricular ejection fraction (also Poster #S18)
T. Ueyama, Wakayama Medical University, Wakayama, Japan
Takotsubo cardiomyopathy: a form of severe, reversible heart failure evoked by emotional distress in post-menopausal women (also Poster #S19)
Question and answer session
Poster viewing and tour
Buffet lunch and roundtable discussion (microphone at each table)
Translating cardiac neuroimaging to clinical research and practice




Poster #S1
Differential diagnostic value of normal uptake but increased 123I-MIBG washout in Parkinsonism
Y Uchiyama, M Momose, C Kondo, K Kusakabe, M Iwata, S Uchiyama
Tokyo, Japan
Poster #S2
123I-meta-iodobenzylguanidine scintigraphy is a useful diagnostic tool to differentiate early phase of Lewy body disease from other movement disorders
T Takeda, S Uchiyama
Tokyo, Japan
Poster #S3
123I-MIBG scintigraphy in PSP, CBD and IPD
M Yoshita, D Noto, K Takahashi, M Yamada
Kanazawa, Japan
Poster #S4
Myocardial sympathetic degeneration correlates with olfactory function in Parkinson’s disease
M Iijima, M Osawa, M Momose, M Suzuki, S Uchiyama
Tokyo, Japan
Poster #S5
MIBG myocardial scintigraphy in the diagnosis of dementia
J Nunomura, M Nishie, A Arai, Y Miki, M Baba
Aomori, Japan
Poster #S6
123I-metaiodobenzylguanidine myocardial scintigraphy and susceptibility weighted-imaging of the substantia nigra in patients with PD
T Maeda, K Nagata, H Toyoshima, T Kinoshita
Akita, Japan
Poster #S7
Longitudinal observation of MIBG myocardial scintigraphy in patients with multiple system atrophy
H Nagayama, M Ueda, M Hamamoto, K Tsukamoto, Y Katayama
Tokyo, Japan
Poster #S8
Preclinical investigation of 11C-phenethylguanidines as radiotracers for quantifying cardiac sympathetic nerve density with PET
DM Raffel, Y-W Jung, G Gu, RA Koeppe, P Sherman, C Quesada
Ann Arbor, MI, USA
Poster #S9
PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes
DM Raffel, RA Koeppe, R Little, C-N Wang, S Liu, L Junck, M Heumann, S Gilman
Ann Arbor, MI, USA
Poster #S10
Importance of renal function of cardiac iodine-123 metaiodobenzylguanidine scintigraphy for predicting prognosis of heart disease patients
T Furuhashi, M Moroi, H Hase, T Kunimasa, R Nakazato, H Fukuda, K Sugi
Tokyo, Japan
Poster #S11
Marked reduction of cardiac 123I-MIBG uptake in REM sleep behavior disorder compared with Parkinson’s disease
K Kashihara, T Imamura, M Ohno, S Kawada
Okayama, Japan
Poster #S12
Evaluation of Parkinson’s disease and related disorders using cardiac MIBG scintigraphy
K Marumoto, K Ichikawa, R Yamada, H Kikuchi, M Nakashita, K Matsumoto, Y Kageyama
Hyogo, Japan
Poster #S13
Translating cardiac neuroimaging to clinical practice: a novel approach to neurogenic orthostatic hypotension
DS Goldstein, Y Sharabi
Bethesda, MD, USA